SpineThera

SPINETHERA TO PRESENT AT DISCOVERY SQUARE INNOVATORS & INVESTORS FORUM

On October 10, 2017 the Mayo Clinic Center for Individualized Medicine, Destination Medical Center, and Medical Alley Association are hosting the Discovery Square Innovators + Investors Forum at the Mayo Civic Center.

Jeff Missling, CEO, will describe the value that SpineThera’s sustained-release injectable steroid, SX600, may deliver to patients, physicians, and payers. SpineThera designed SX600 with the goal of providing patients long-term back pain relief from a single epidural steroid injection.  Mr. Missling is scheduled to speak at 3:00 pm.   

About SpineThera:

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug.

About the event:

This half-day event features leaders in the healthcare and technology innovation community who are helping grow Minnesota’s healthcare economy.  Following the panel discussions and company presentations, the Investors & Innovators Reception (5:00–7:30 pm) will provide a business casual setting to connect with innovators, investors, industry executives, venture capitalists, philanthropists, key opinion leaders from academia, and key Mayo leadership to explore opportunities for collaboration.

 

SpineThera Receives $2 Million Grant From U.S. Army

SpineThera, Inc., a privately held pharmaceutical company, announced today that the United States Army has awarded the company a grant to support the further development of SX600, a sustained-release, injectable, micro-suspension corticosteroid in development to address the unique requirements of an epidural injection to treat back pain.

Back pain is a significant medical problem for the Armed Forces resulting in evacuations, treatments, and training of replacement personnel. Prevalence among deployed personnel is 21-27%, and it is the most common condition for which medical treatment is sought in the military.

Jeff Missling, Founder and CEO of SpineThera, stated, “We are honored and thankful to receive this $2,019,442 award from the United States Army. Army doctors have shown that treating back pain in forward deployed pain clinics results in return-to-duty rates greater than 90%, but have also reported that 35% of coalition forces who received an epidural steroid injection for back pain returned to these forward deployed pain clinics for another injection. The typical interval between injections was 2-4 weeks. Our goal with SX600 is to offer a long-acting injectable drug that provides pain relief and reduces the need for repeat or frequent epidural steroid injections. Knowing that our drug has potential benefits to deployed military personnel, in addition to non-deployed military personnel and the general patient population, adds further meaning to our work. We aim to offer back pain patients a better treatment option than exists today.”

About the Award:

The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Broad Agency Announcement under Award No. W81XWH-17-1-0014. Opinions, interpretations, conclusions and recommendations are those of the SpineThera and are not necessarily endorsed by the Department of Defense. In conducting research using animals, SpineThera adheres to the laws of the United States and regulations of the Department of Agriculture.

About SpineThera:

SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600 is an investigational drug.